share_log

HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target

Moomoo 24/7 ·  Feb 29 15:06

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment